Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat, +27

New England Journal of Medicine

Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission

M. Ryan Corces, Wan‐Jen Hong, Irving L. Weissman, +2

Proceedings of the National Academy of Sciences

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

Steven M. Chan, Danièl Thomas, M. Ryan Corces, +7

Nature Medicine

Hematological MalignancyIsocitrate Dehydrogenase 1Mixed-phenotype Acute LeukemiaAcute Myeloid LeukemiaGenetics +5

A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells

Andreas Reinisch, Danièl Thomas, M. Ryan Corces, +6

Nature Medicine

Improved EngraftmentCell TherapyXenotransplantationMarrow TransplantationStem Cell Mobilization +7

Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation

Claire Mazumdar, Ying Shen, Seethu Xavy, +12

Cell stem cell

Developmental BiologyMedicineStem Cell MobilizationMixed-phenotype Acute LeukemiaHematology +6

Tuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands

Ignacio Moraga, Gerlinde Wernig, Stephan Wilmes, +16

Cell

InflammationCytokineRe-orienting Dimer GeometrySignal TransductionSignaling Pathway +8

Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study

Daniel A. Pollyea, Keith W. Pratz, Anthony Letai, +12

American Journal of Hematology

Toxicity from radiation therapy associated with abnormal transcriptional responses to DNA damage

Kerri E. Rieger, Wan‐Jen Hong, Virginia Goss Tusher, +3

Proceedings of the National Academy of Sciences

Targeting <scp>BCL</scp>‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma

Jonathan L. Kaufman, Cristina Gasparetto, Fredrik Schjesvold, +18

American Journal of Hematology

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

Naval Daver, Monique Dail, Jacqueline S. Garcia, +24

Blood

Mixed-phenotype Acute LeukemiaPharmacotherapyTranslational PharmacologyMyeloid NeoplasiaHematological Malignancy +16